Unibest
← Back to patent-cliff list

Obicetrapib

Tier C — Watch / trade

Obicetrapib

Mitsubishi Tanabe Pharma Corporation
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:CETP

Indications (approved):Myocardial infarction, Atherosclerosis, Hypercholesterolaemia, Hyperlipoproteinaemia type II, 代谢病, 高脂蛋白血症, 先天性代谢缺陷病, Dyslipidaemia

Regional status

US
Phase III
2021-12-15
EU
Phase III
2021-12-15
China
Phase III
2021-12-15
Japan
Phase III
2021-12-15

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 4 · Total yield 375 g
OBIC-001402-43-7OBIC-002131347-76-7OBIC-003474645-90-4OBIC-004952582-00-2OBIC-005952581-99-6API · Obicetrapib
CodeCAS No.Intermediate
OBIC-001402-43-71-bromo-4-(trifluoromethyl)benzene
OBIC-002131347-76-7(R)-3-aminopentanoic acid
OBIC-003474645-90-4(R)-3-((4-(trifluoromethyl)phenyl)amino)pentanoic acid
OBIC-004952582-00-2(R)-2-ethyl-6-(trifluoromethyl)-2,3-dihydroquinolin-4(1H)-one
OBIC-005952581-99-6(R,E)-2-ethyl-6-(trifluoromethyl)-2,3-dihydroquinolin-4(1H)-one oxime
OptimisedRoute 2Steps 4 · Total yield 2.58 g
OBIC-006455-14-1OBIC-007—OBIC-0081878192-73-4OBIC-00971607-32-4OBIC-010—API · Obicetrapib
CodeCAS No.Intermediate
OBIC-006455-14-14-(trifluoromethyl)aniline
OBIC-007-N-(2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)formamide
OBIC-0081878192-73-42-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-amine
OBIC-00971607-32-4(2R,3R)-2,3-bis((4-methylbenzoyl)oxy)succinic acid hydrate
OBIC-010-(2R,4S)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-amine (2R,3R)-2,3-bis((4-methylbenzoyl)oxy)succinate

Frequently asked questions

What are the approved indications of Obicetrapib?

Approved indications include: Myocardial infarction, Atherosclerosis, Hypercholesterolaemia, Hyperlipoproteinaemia type II, 代谢病, 高脂蛋白血症, 先天性代谢缺陷病, Dyslipidaemia.

When does the Obicetrapib patent expire?

No public expiry year is available for Obicetrapib yet; this page updates once verified.

How many synthesis routes are recorded for Obicetrapib?

2 synthesis routes are recorded; the shortest is 4 steps with 375 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Obicetrapib intermediates?

All intermediates in Obicetrapib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Obicetrapib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-06